Knowledge sharing expertise firm Datavant has expanded its collaboration with pharmaceutical firm Boehringer Ingelheim to assist Boehringer’s real-world proof initiatives.
The prolonged collaboration goals to leverage Datavant’s privacy-preserving tokenization and information connectivity applied sciences to strengthen scientific growth and provoke methods throughout 75 extra scientific trials and a number of new molecular entities.
By means of Datavant Join, a platform that helps stability information utility with information privateness, Boehringer can adeptly discover and consider third-party information sources with out transferring or sharing underlying information.
By making use of Datavant’s expertise throughout a broad portfolio of trials and launches, Boehringer Ingelheim goals to extend the mixing of real-world information into drug growth.
Moreover, groups will implement tokenization in a phased rollout to make sure seamless integration with Boehringer Ingelheim’s current analysis infrastructure.
Arnaub Chatterjee, common supervisor and president, life sciences, ecosystem and public sector for Datavant, stated by enabling safe and environment friendly information linkage at scale, Boehringer Ingelheim is establishing a brand new benchmark for medical analysis.
“This partnership exemplifies how expertise can reshape healthcare and enhance affected person outcomes,” Chatterjee stated in an announcement.
Paul Petraro, government director and head of the true world proof analytics middle of excellence for Boehringer Ingelheim, stated funding in real-world information underscores Boehringer Ingelheim’s dedication to utilizing cutting-edge applied sciences to advance medical analysis.
“By increasing this strategy throughout extra trials and business launches, we’re positioned to drive extra personalised and cost-effective remedies, in the end reworking affected person care,” Petraro stated in an announcement.
THE LARGER TREND
In 2023, Socially Determined partnered with Datavant to supply life sciences firms with information on social threat drivers to enhance well being fairness and affected person outcomes.
Socially Decided makes use of information to supply insights into the social determinants of well being, together with elements like entry to meals, housing and transportation.
In 2021, psychedelic-inspired biotech firm MindMed tapped Datavant to assist hyperlink its scientific trial information with exterior proof from different scientific trials and real-world information sources.
Utilizing Datavant’s privacy-protecting expertise, MindMed created datasets to know the real-world remedy, service utilization and healthcare experiences of sufferers with psychiatric and substance use problems. By growing its information, MindMed hoped to raised develop its product pipeline.
In 2020, Datavant closed $40 million in Series B funding. Transformation Capital led the elevate, which noticed contributions from new backers Johnson & Johnson Innovation – JJDC and Cigna Ventures and current traders Roivant Sciences and Flex Capital.
In 2021, Datavant merged with Ciox Well being in a deal value $7 billion.
In 2023, Boehringer Ingelheim and tech big IBM teamed as much as harness the facility of generative AI and foundation models to additional biologic drug discovery.
The partnership leveraged IBM’s basis mannequin applied sciences, consisting of pre-trained, large-scale neural community architectures, to speed up the identification of novel antibodies important for therapeutic growth.
That very same yr, Boehringer Ingelheim and digital therapeutic firm Click Therapeutics initiated a scientific trial known as CONVOKE Study, which evaluated prescription digital therapeutics as an adjunct remedy for schizophrenia.
The randomized trial included 432 members and in contrast prescription digital therapeutics to the usual of care utilizing antipsychotic remedy over the course of 16 weeks.
Trending Merchandise
